Structuring investor outreach for a $8.2M Series A round

A US-based Biotech startup was preparing for its Series A round after reaching important product and research milestones. The company had strong scientific validation, early clinical interest, and a clear market need, but its fundraising process needed to be more structured.

The team had already received interest from a few investors, but the investor pipeline was not clearly prioritized. The company also needed a stronger fundraising narrative that could speak to both biotech investors and healthtech-focused funds. Its materials had to explain the science clearly while also showing the commercial potential, market size, regulatory path, and long-term growth opportunity.

RockinGrow supported the startup with fundraising narrative refinement, pitch deck review, investor FAQ preparation, data room structuring and targeted investor outreach. The investor pipeline was segmented across biotech VC funds, healthtech investors, life sciences funds and strategic healthcare investors.

The outreach process helped the company reach investors that were more aligned with its stage, sector and investment thesis. By improving the fundraising story and organizing the investor materials, the startup was able to create stronger conversations with both institutional and strategic investors.

The company successfully closed $8.2M Series A round with participation from biotech-focused VC funds, healthtech investors, and strategic healthcare investors.

Result: $8.2M Series A closed with biotech, healthtech, and strategic healthcare investors.